Work

205P Transarterial chemoembolization with immune checkpoint inhibitors and anti-VEGF antibody/tyrosine kinase inhibitors as first-line treatment for intermediate-stage hepatocellular carcinoma (CHANCE2202): A target trial emulation study

Year: 2024

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2024.10.225

Authors: J-J. Chen, Z-C. Jin, B-Y. Zhong, H. Zhu, G. Teng

Institutions: Zhongda Hospital Southeast University, Southeast University, First Affiliated Hospital of Soochow University

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Natural Science Foundation of China, National Key Research and Development Program of China

Awards: G1132155481, G392616567, G8356858166, G8479523980

OpenAlex ID: W4405134836

FWCI:

Cites:

Cited by:

Related to: 10